JNK3 as Therapeutic Target and Biomarker in Neurodegenerative and Neurodevelopmental Brain Diseases
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
The c-Jun N-terminal kinase 3 (JNK3) is the JNK isoform mainly expressed in the brain. It is the most responsive to many stress stimuli in the central nervous system from ischemia to Aβ oligomers toxicity. JNK3 activity is spatial and temporal organized by its scaffold protein, in particular JIP-1 and β-arrestin-2, which play a crucial role in regulating different cellular functions in different cellular districts. Extensive evidence has highlighted the possibility of exploiting these adaptors to interfere with JNK3 signaling in order to block its action. JNK plays a key role in the first neurodegenerative event, the perturbation of physiological synapse structure and function, known as synaptic dysfunction. Importantly, this is a common mechanism in many different brain pathologies. Synaptic dysfunction and spine loss have been reported to be pharmacologically reversible, opening new therapeutic directions in brain diseases. Being JNK3-detectable at the peripheral level, it could be used as a disease biomarker with the ultimate aim of allowing an early diagnosis of neurodegenerative and neurodevelopment diseases in a still prodromal phase.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases
Cargnello, M., & Roux, P. P. (2011) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00031-10 · Cited by 3,274
Mitogen-Activated Protein Kinases: Specific Messages from Ubiquitous Messengers
Schaeffer, H. J., & Weber, M. J. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.4.2435 · Cited by 1,600
Regulation of NMDA receptor trafficking by amyloid-β
Snyder, E. M., Nong, Y., Almeida, C. G., Paul, S., Moran, T., Choi, E. Y., Nairn, A. C., Salter, M. W., Lombroso, P. J., Gouras, G. K., et al. (2005) · Nature Neuroscience · doi:10.1038/nn1503 · Cited by 1,561
Whitmarsh, A. J., & Davis, R. J. (1996) · Journal of Molecular Medicine · doi:10.1007/s001090050063 · Cited by 1,543
A peptide inhibitor of c-Jun N-terminal kinase protects against excitotoxicity and cerebral ischemia
Borsello, T., Clarke, P. G. H., Hirt, L., Vercelli, A., Repici, M., Schorderet, D. F., Bogousslavsky, J., & Bonny, C. (2003) · Nature Medicine · doi:10.1038/nm911 · Cited by 658
Self-citationSchneider, L. S., Mangialasche, F., Andreasen, N., Feldman, H., Giacobini, E., Jones, R., Mantua, V., Mecocci, P., Pani, L., Winblad, B., et al. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12191 · Cited by 651
Cargo of kinesin identified as JIP scaffolding proteins and associated signaling molecules
Verhey, K. J., Meyer, D., Deehan, R., Blenis, J., Schnapp, B. J., Rapoport, T. A., & Margolis, B. (2001) · The Journal of Cell Biology · doi:10.1083/jcb.152.5.959 · Cited by 609
Cell-Permeable Peptide Inhibitors of JNK
Bonny, C., Oberson, A., Negri, S., Sauser, C., & Schorderet, D. F. (2001) · Diabetes · doi:10.2337/diabetes.50.1.77 · Cited by 571
The JIP Group of Mitogen-Activated Protein Kinase Scaffold Proteins
Yasuda, J., Whitmarsh, A. J., Cavanagh, J., Sharma, M., & Davis, R. J. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.10.7245 · Cited by 458 · cited 2×
“Interestingly, both JIP-1 and JIP-2 can form homodimers but also heterodimers with each other [59].”
BackgroundZhuang, Z.-Y., Kawasaki, Y., Tan, P.-H., Wen, Y.-R., Huang, J., & Ji, R.-R. (2007) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2006.11.003 · Cited by 371
JNK signaling in cancer cell survival
Wu, Q., Wu, W., Fu, B., Shi, L., Wang, X., & Kuca, K. (2019) · Medicinal Research Reviews · doi:10.1002/med.21574 · Cited by 322 · cited 1×
“JNK2 has also showed a key role in autoimmune disorders, such as rheumatoid arthritis [21,22], asthma [23] and cancer [24,25], and in the regulation of cancer cell survival [26].”
BackgroundChen, X., Levy, J. M., Hou, A., Winters, C., Azzam, R., Sousa, A. A., Leapman, R. D., Nicoll, R. A., & Reese, T. S. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1517045112 · Cited by 310
Interaction of a mitogen-activated protein kinase signaling module with the neuronal protein JIP3
Kelkar, N., Gupta, S., Dickens, M., & Davis, R. J. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.3.1030-1043.2000 · Cited by 281 · cited 1×
“In addition, JIP-3 itself is a JNK target, since it can be phosphorylated only by JNK and not by p38 and ERK [61].”
BackgroundKim, M. J., Futai, K., Jo, J., Hayashi, Y., Cho, K., & Sheng, M. (2007) · Neuron · doi:10.1016/j.neuron.2007.09.007 · Cited by 278
Sun, B., Halabisky, B., Zhou, Y., Palop, J. J., Yu, G., Mucke, L., & Gan, L. (2009) · Cell Stem Cell · doi:10.1016/j.stem.2009.10.003 · Cited by 205
Crystal structure of JNK3: a kinase implicated in neuronal apoptosis
Xie, X., Gu, Y., Fox, T., Coll, J. T., Fleming, M. A., Markland, W., Caron, P. R., Wilson, K. P., & Su, M. S.-S. (1998) · Structure · doi:10.1016/s0969-2126(98)00100-2 · Cited by 198 · cited 1×
“However, there are two clusters of divergent regions, identified from the amino acid sequence alignment, that are located next to each other on the protein surface in the C-terminal lobe of JNK3 [45].”
BackgroundCoffey, E. T., Smiciene, G., Hongisto, V., Cao, J., Brecht, S., Herdegen, T., & Courtney, M. J. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-11-04335.2002 · Cited by 184
cJun NH2-terminal kinase 1 (JNK1): Roles in metabolic regulation of insulin resistance
Sabio, G., & Davis, R. J. (2010) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2010.04.004 · Cited by 170
Docking interactions in the mitogen-activated protein kinase cascades
Tanoue, T., & Nishida, E. (2002) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(02)00188-2 · Cited by 134 · cited 1×
“The first is the simplest, where the MAPK cascade members interact by direct protein–protein interactions [37]; the second module is assembled by the scaffold protein that links together three different MAP kinases.”
BackgroundLisnock, J., Griffin, P., Calaycay, J., Frantz, B., Parsons, J., O'Keefe, S. J., & LoGrasso, P. (2000) · Biochemistry · doi:10.1021/bi992410+ · Cited by 79 · cited 2×
“Concerning JNK3, while phosphorylation of Thr by MKK7 results in significant activation of JNK3, phosphorylation of Thr by MKK4 alone triggers only low levels of JNK3 activation in vitro; however, MKK4 does increase the activity of JNK that has already undergone Thr phosphorylation [8].”
BackgroundChiquet, C., Aptel, F., Creuzot-Garcher, C., Berrod, J.-P., Kodjikian, L., Massin, P., Deloche, C., Perino, J., Kirwan, B.-A., de Brouwer, S., et al. (2017) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2016.10.012 · Cited by 52
Cited by
Hypothesis: JNK signaling is a therapeutic target of neurodegenerative diseases
Zhao, Y., Kuca, K., Wu, W., Wang, X., Nepovimova, E., Musilek, K., & Wu, Q. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12370 · Cited by 79
Li, Z., Yin, B., Zhang, S., Lan, Z., & Zhang, L. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115817 · Cited by 54
Early onset senescence and cognitive impairment in a murine model of repeated mTBI
Schwab, N., Ju, Y., & Hazrati, L.-N. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01190-x · Cited by 39
Huang, R., Zhu, Z., Wu, Q., Bekhit, A. E.-D. A., Wu, S., Chen, M., Wang, J., & Ding, Y. (2023) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2021.1975093 · Cited by 23
Metadata
- Authors
- Musi, C. A., Agrò, G., Santarella, F., Iervasi, E., & Borsello, T.
- Venue
- Cells
- Publisher
- MDPI AG
- Published
- 2020-09-28
- Volume
- 9
- Issue
- 10
- Pages
- 2190
- ISSN
- 2073-4409 (ISSN-L)
- OpenAlex
- W3087975979
- Cited by
- 73
- References
- 21
- FWCI
- 3.29
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.